

1 **Complete Skin Clearance is Associated with the Greatest**
2 **Benefits to Health-Related Quality of Life and Perceived**
3 **Symptoms for Patients with Psoriasis**

4

5 **Supplementary Material**

6

7 Matthias Augustin,¹ Alice B. Gottlieb,² Mark Lebwohl,² Andreas Pinter,³

8 Richard B. Warren,^{4,5} Luis Puig,⁶ Rhys Warham,^{7,8} Jérémy Lambert,⁹

9 Susanne Wiegratz,¹⁰ Balint Szilagyi,¹⁰ Andrew Blauvelt¹¹

10

11 ¹Institute for Health Services Research in Dermatology and Nursing (IVDP),
12 University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany;

13 ²Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New
14 York, New York, USA; ³University Hospital Frankfurt, Frankfurt am Main, Germany;

15 ⁴Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Manchester, UK;

16 ⁵NIHR Manchester Biomedical Research Centre, Manchester University NHS
17 Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK;

18 ⁶Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona,
19 Spain; ⁷Veramed, London, UK; ⁸UCB, Slough, UK; ⁹UCB, Colombes,

20 France; ¹⁰UCB, Monheim am Rhein, Germany; ¹¹Oregon Medical Research
21 Center, Portland, Oregon, USA


22

23 Correspondence to: Matthias Augustin; m.augustin@uke.de


24 Institute for Health Services Research in Dermatology and Nursing (IVDP), University
25 Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

26

1 **Figure S1. Model-estimated proportions of patients achieving scores of 0 in**
 2 **each DLQI item at different PASI improvement levels**
 3 **A) Over 16 weeks**



4 **B) Over 2 years**



5 A mixed-effects logistic regression model used data pooled across all trial visits and
 6 treatments over a) 16 weeks and b) 2 years of BE RADIANT to estimate the proportions of
 7 patients achieving DLQI item score=0 at specific PASI improvement levels. [a] For DLQI
 8 Items 3–10, an item score of 0 ('not relevant') may mean that the activity in question is not
 9 possible, sometimes due to severe disease, rather than there being no impact of disease on
 10 the activity. Model estimates were calculated with baseline DLQI item scores equal to the
 11 baseline median for the respective populations (16 weeks: all randomised patients; 2 years:
 12 patients who entered the OLE). DLQI: Dermatology Life Quality Index; PASI: Psoriasis Area
 13 and Severity Index.

1 **Table S1. Data collection schedule**

2

	Week of BE RADIANT																				
Outcome	0	1	2	4	8	12	16	20	24	28	32	36	40	44	48^a	52	56	64	72	84	96
PASI	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
DLQI	X			X	X	X	X				X				X				X		X
P-SIM	X			X	X	X	X				X				X		X	X	X	X	X

3 [a] The OLE began at Week 48. DLQI: Dermatology Life Quality Index; OLE: open-label extension; PASI: Psoriasis Area and Severity Index; P-SIM: Psoriasis
 4 Symptoms and Impacts Measure.

5